Search research articles
Contact Us
Filters
Showing results (1-10 of 61) with videos related to
Page
of 7
Sort By:
Journal for Immunotherapy of Cancer
|
August 24, 2018
The age of enlightenment in melanoma immunotherapy
Mark R Albertini
Cytometry. Part a : the Journal of the International Society for Analytical Cytology
|
March 21, 2012
OMIP-008: measurement of Th1 and Th2 cytokine polyfunctionality of human T cells
Cindy L Zuleger, Mark R Albertini
WMJ : Official Publication of the State Medical Society of Wisconsin
|
January 5, 2016
Incidence, Survival, and Mortality of Malignant Cutaneous Melanoma in Wisconsin, 1995-2011
Molly Peterson, Mark R Albertini, Patrick Remington
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
September 26, 2007
MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis
Jason A Dubovsky, Mark R Albertini, Douglas G McNeel
Transfusion Medicine Reviews
|
July 13, 2004
Dendritic cell-based immunotherapy for cancer and relevant challenges for transfusion medicine
Ching Y Voss, Mark R Albertini, James S Malter
Cancer Chemotherapy and Biological Response Modifiers
|
August 23, 2005
Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma
Mark R Albertini, Jacquelyn A Hank, Paul M Sondel
Seminars in Nuclear Medicine
|
October 16, 2020
FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls
Steve Y Cho, Daniel T Huff, Robert Jeraj, et al.
Case Reports in Gastrointestinal Medicine
|
July 26, 2021
Retrograde Balloon-Assisted Deep Enteroscopy in the Diagnosis of Metastatic Melanoma
William Barge, Mark R Albertini, Christopher Cold, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
January 20, 2007
Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity
Zane C Neal, Mary K Bates, Mark R Albertini, et al.
Expert Opinion on Investigational Drugs
|
June 25, 2009
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma
Brett H Yamane, Jacquelyn A Hank, Mark R Albertini, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 61) with videos related to
Sort By:
Page
of 7
Journal for Immunotherapy of Cancer
|
August 24, 2018
The age of enlightenment in melanoma immunotherapy
Mark R Albertini
Cytometry. Part a : the Journal of the International Society for Analytical Cytology
|
March 21, 2012
OMIP-008: measurement of Th1 and Th2 cytokine polyfunctionality of human T cells
Cindy L Zuleger, Mark R Albertini
WMJ : Official Publication of the State Medical Society of Wisconsin
|
January 5, 2016
Incidence, Survival, and Mortality of Malignant Cutaneous Melanoma in Wisconsin, 1995-2011
Molly Peterson, Mark R Albertini, Patrick Remington
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
September 26, 2007
MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis
Jason A Dubovsky, Mark R Albertini, Douglas G McNeel
Transfusion Medicine Reviews
|
July 13, 2004
Dendritic cell-based immunotherapy for cancer and relevant challenges for transfusion medicine
Ching Y Voss, Mark R Albertini, James S Malter
Cancer Chemotherapy and Biological Response Modifiers
|
August 23, 2005
Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma
Mark R Albertini, Jacquelyn A Hank, Paul M Sondel
Seminars in Nuclear Medicine
|
October 16, 2020
FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls
Steve Y Cho, Daniel T Huff, Robert Jeraj, et al.
Case Reports in Gastrointestinal Medicine
|
July 26, 2021
Retrograde Balloon-Assisted Deep Enteroscopy in the Diagnosis of Metastatic Melanoma
William Barge, Mark R Albertini, Christopher Cold, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
January 20, 2007
Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity
Zane C Neal, Mary K Bates, Mark R Albertini, et al.
Expert Opinion on Investigational Drugs
|
June 25, 2009
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma
Brett H Yamane, Jacquelyn A Hank, Mark R Albertini, et al.
Page
of 7